FDA Approves scPharmaceuticals' Self-Administered Med For Congestion in Chronic Heart Failure

• The FDA has approved scPharmaceuticals Inc's (NASDAQ: SCPH) Furoscix (furosemide injection), a proprietary formulation of furosemide delivered via an On-Body Infusor for congestion due to fluid overload in heart failure patients.

• Furoscix is not indicated for emergencies or in patients with acute pulmonary edema. Furoscix Infusor will deliver only an 80-mg dose.

• The company says Furoscix is the first and only FDA-approved subcutaneous loop diuretic that delivers IV equivalent diuresis at home via the Furoscix Infusor.

• Related: scPharma's Furoscix Can Potentially Cut Hospital Admission/Readmission Costs For Heart Failure Patients.

• "We are preparing to optimize commercialization efforts to offer FUROSCIX to patients in the first quarter of next year to drive rapid patient adoption to meet the needs of the $5.9 billion addressable market in the U.S," said John Tucker, President, and CEO.

• Concurrently, scPharmaceuticals secured a $100 million secured debt facility from Oaktree Capital Management, L.P.

• The company will use the funds and cash on hand to repay indebtedness and execute the launch of Furoscix.

• Price Action: SCPH shares are down 7.23% at $4.62 during the premarket session on the last check Monday.

See more from Benzinga

• Tesla's Stock Weakness Presents Opportunity, BMW Posts Lower Quarterly Sales, Lockheed To Resume Delivery Of F-35 Jets: Top Stories Monday, Oct. 10

• Saudi Aramco To Maintain Oil Deliveries To Asian Clients Despite OPEC+ Cuts

• Putin Ally Declares Russia Will Target This City First If World War 3 Erupts

Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.

© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.